A Protein–Protein Interaction Network for Human Inherited Ataxias and Disorders of Purkinje Cell Degeneration  by Lim, Janghoo et al.
ResourceA Protein–Protein Interaction Network
for Human Inherited Ataxias and
Disorders of Purkinje Cell Degeneration
Janghoo Lim,1 Tong Hao,4 Chad Shaw,1 Akash J. Patel,1 Ga´bor Szabo´,4,5 Jean-Franc¸ois Rual,4 C. Joseph Fisk,1
Ning Li,4 Alex Smolyar,4 David E. Hill,4 Albert-La´szlo´ Baraba´si,4,5 Marc Vidal,4 and Huda Y. Zoghbi1,2,3,*
1Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA
2Departments of Pediatrics and Neuroscience, Baylor College of Medicine, Houston, TX 77030, USA
3Howard Hughes Medical Institute, USA
4Center for Cancer Systems Biology and Department of Cancer Biology, Dana-Farber Cancer Institute and Department of
Genetics, Harvard Medical School, Boston, MA 02115, USA
5Center for Complex Network Research and Department of Physics, University of Notre Dame, Notre Dame, IN 46556, USA
*Contact: hzoghbi@bcm.tmc.edu
DOI 10.1016/j.cell.2006.03.032SUMMARY
Many human inherited neurodegenerative dis-
orders are characterized by loss of balance
due to cerebellar Purkinje cell (PC) degenera-
tion. Although the disease-causing mutations
have been identified for a number of these dis-
orders, the normal functions of the proteins
involved remain, in many cases, unknown. To
gain insight into the function of proteins in-
volved in PC degeneration, we developed an
interaction network for 54 proteins involved in
23 inherited ataxias and expanded the network
by incorporating literature-curated and evolu-
tionarily conserved interactions. We identified
770 mostly novel protein–protein interactions
using a stringent yeast two-hybrid screen; of
75 pairs tested, 83% of the interactions were
verified in mammalian cells. Many ataxia-caus-
ing proteins share interacting partners, a subset
of which have been found to modify neurode-
generation in animal models. This interactome
thus provides a tool for understanding patho-
genic mechanisms common for this class of
neurodegenerative disorders and for identifying
candidate genes for inherited ataxias.
INTRODUCTION
Many human inherited neurodegenerative disorders, such
as the spinocerebellar ataxias (SCAs), are characterized
by cerebellar Purkinje cell (PC) degeneration that causes
ataxia, or loss of balance and coordination (Sakaguchi
et al., 1996; Engert et al., 2000; Zoghbi and Orr, 2000;
Moore et al., 2001; Sun et al., 2001; Matsuda et al.,
2004; Taroni and DiDonato, 2004). Similarly, several ataxicmouse mutants also display PC degeneration phenotypes
(Hamilton et al., 1996; Fernandez-Gonzalez et al., 2002;
Klein et al., 2002; Isaacs et al., 2003; Noveroske et al.,
2005). The inherited ataxias are caused by either gain-of-
function or loss-of-function mutations in seemingly unre-
lated genes (Zoghbi and Orr, 2000; Taroni and DiDonato,
2004). To date, genes have been identified for over 23
inherited ataxias, but the normal function of the majority
of ataxia-causing proteins is poorly understood. Further-
more, although several human and mouse ataxias share
similarmotor dysfunction and cell-specific neuropathology,
the molecular mechanism(s) mediating such overlapp-
ing features are largely unknown. Independent disease-
based studies have revealed the importance of protein–
protein interactions in understanding the normal function
of the disease-causing protein and are beginning to iden-
tify pathways that could be targeted therapeutically (Stef-
fan et al., 2001; Yoshida et al., 2002; Chen et al., 2003;
Goehler et al., 2004; Ravikumar et al., 2004; Kaytor et al.,
2005; Tsuda et al., 2005).
Because of the overlap in phenotypes and the promi-
nence of PC pathology in human and mouse ataxias, we
hypothesized that the gene products involved in this class
of neurodegenerative diseases might play roles in com-
monmolecular pathways that are essential for PC function
and survival. Furthermore, we reasoned that insight into
the cellular functions of ataxia-causing proteins would
deepen our understanding of the molecular events under-
lying the PC pathology. One approach to characterizing
unknown proteins is to identify interacting protein partners
and link the interacting pairs to known cellular pathways.
A first-draft human protein–protein interaction network
has recently been generated (Rual et al., 2005; Stelzl
et al., 2005). Undoubtedly, this network will be a valuable
resource for many biological studies. Nevertheless, to un-
cover pathogenic mechanisms requires characterizing
in greater detail the network around specific groups of
proteins that are implicated in a particular class of disor-
ders. We therefore set out to develop a proteome-scaleCell 125, 801–814, May 19, 2006 ª2006 Elsevier Inc. 801
protein–protein interactionnetwork for ataxia-causingpro-
teins. Suchanetworkwill havemoredeptharoundproteins
involved in a specific biological problem and will be more
useful to disease-oriented researchers than the larger hu-
man interaction networks. Furthermore, phenotype-based
interaction networks aremore likely to bring out someof the
key interactions mediating pathogenesis than the broader
and less deeply developed entire proteome networks.
In this study, we developed a stringent protein–protein
interaction network for the 20 or more different inherited
cerebellar ataxias characterized by PC degeneration. This
phenotype-based interactome network revealed several
previously unsuspected interactions between the various
ataxia-causing proteins. Bioinformatic analysis showed
high connectivity between different ataxia-causing pro-
teins and revealed common cellular pathways that might
lead to PC dysfunction and degeneration. Importantly,
many genetic modifier proteins identified by studies using
mouse and Drosophila disease models showed direct
physical interactions with the corresponding disease pro-
tein, linking known genetic pathways within the protein in-
teraction network. Finally, this protein interaction network
provides candidate genes for cerebellar ataxias whose
genetic defect has not yet been identified.
RESULTS
Three Yeast Two-Hybrid Screens for Proteins
Involved in Inherited Ataxias
To generate a proteome-scale interactome network for in-
herited ataxias, we selected 23 human cDNAs encoding
proteins directly involved in 23 different types of inherited
ataxias (Table 1). We refer to these as ‘‘ataxia-causing’’
proteins to indicate that mutations in the genes encoding
them cause ataxia in humans or mice. This list includes
11 recessive and 12 dominant ataxias encompassing the
polyglutamine-mediated SCAs. We also selected 31 addi-
tional proteins that either interact with the ataxia-causing
proteins or are paralogs of such proteins (Table S1). We
refer to this extended group as ‘‘ataxia-associated pro-
teins.’’ A total of 122 full-length or partial open reading
frames (ORFs) encoding 54 different proteins were cloned
into Gateway-compatible yeast two-hybrid Y2H destina-
tion vectors to generate GAL4 DNA binding domain
(DB)- or activation domain (AD)-fusion proteins, referred
to as DB-ataxia or AD-ataxia constructs, respectively (Ta-
ble S2). Using these clones, we screened both the human
ORFeome v1.1 (hORFeome) (Rual et al., 2004; Rual et al.,
2005) and adult brain cDNA libraries (Figure 1A).
To screen the hORFeome, we performed matrix-based
mating type screens in 96-well format. The DB-ataxia
transformed MaV203 yeasts were individually mated with
MaV103 AD-188 ORFs minilibrary pools (Rual et al.,
2005). As a second round of screening, we tested recipro-
cal pair-wise interactions between AD-ataxia preys and
DB-hORFeome baits. We chose to screen both the AD-
and DB-hORFeome clones for two reasons. First, we rec-
ognized that the folding of the fusion protein in Y2Hvectors802 Cell 125, 801–814, May 19, 2006 ª2006 Elsevier Inc.might vary depending on the vector backbone. Second, by
using AD-ataxia clones we could include autoactivating
baits in our screen. From these reciprocal hORFeome
screens, we identified 269 potential protein–protein inter-
actions involving 36 different ataxia-associated proteins
(Figure 1B; Table S3).We found 14 interactions in common
between theAD- andDB-hORFeomescreens. Theoverlap
comprises 5.2% (14/269) of the observed interactions,
which is typical for reciprocal ORFeome studies (Rual
et al., 2005).
Because the inherited ataxias affect the central nervous
system, we reasoned that it is important to screen a library
that represents the affected tissue. We performed a third
screen using adult human brain cDNA library and identi-
fied 530 potential protein–protein interactions (Figure 1B;
Table S3).
In total, the hORFeome and the brain cDNA library
screens revealed 770 protein–protein interactions involv-
ing 42 ataxia-associated baits and 561 interacting prey
proteins (Figure 1B; Table S3). Interestingly, 29 pairs of
protein–protein interactions were identified as common
to both screens, revealing the advantage of performing
hORFeome and brain cDNA library screens in parallel.
The vast majority (741/770 = 96%) of the Y2H interactions
we identified are novel, with only 29 interactions having
been reported previously (Table S4). We subdivided the
Y2H interactions into two classes based on the number
of clones identified for each interacting protein (Table
S3). Core-1 interacting proteins were those for which
more than three independent clones were found, whereas
Core-2 had less than three clones.
Validation of Y2H Interactions by Coaffinity
Purification and Computational Analyses
To validate the Y2H interactions, we randomly sampled in-
teracting pairs and tested themusing coaffinity purification
co-AP glutathione-S-transferase (GST) pull-down assays
in human HEK293T cells (Li et al., 2004; Rual et al., 2005).
Proteins that have more interactions than others appeared
more frequently in thesampledset.Of75 interactions (about
10% of all interactions) assayed, 62 (or 83%) were con-
firmed by the co-AP assays (Figures 2 and S1 and Table
S3). The co-AP results showed a similar success rate be-
tween Core-1 (80%) and Core-2 (86%) datasets (Table
S3). The similarly high success rate of co-AP validation sug-
gests that the quality of the Y2H screens is very good and
that both Core-1 and Core-2 Y2H interactions are reliable.
In addition to the experimental validation, we performed
bioinformatic analyses to confirm the experimental Y2H
interactions (see Supplemental Data). We implemented
a coannotation analysis using the cellular component
branch of Gene Ontology (GO). We found that 72% of
the Y2H interactions that have known compartment anno-
tations involve proteins that colocalize to the same com-
partment. This is a high colocalization rate, given that
GOannotations are not comprehensive and that biological
reagents to detect all possible subcellular localizations are
not available. We extended this analysis to examine the
biological process andmolecular function branches of the
GO. We found that 98% of the Y2H interactions are coan-
notated in at least one GO branch.
Protein–Protein Interaction Network for Inherited
Cerebellar Ataxias
Analysis of the Y2H interaction data revealed one large
interconnected network consisting of 752 protein–protein
interactions between 36 ataxia-associated proteins and
541 prey proteins (Figure 3). The finding of a single domi-
nant connected component in our network suggests that
proteins involved in inherited cerebellar ataxias are func-
tionally linked. Thirteen inherited ataxia-causing bait pro-
teins were linked either directly or through common inter-
acting proteins within the large component. In contrast,
ten ataxia-causing proteins had only a few or no Y2H inter-
actors and were isolated from the main component (Fig-
ure 3). These ten proteins were PSAP, RORA, TBP,
AGTPBP1, CACNA1A, ATXN10, PPP2R2B, ATM, PRND,
and AF4. These proteins may have had a limited number
of partners or been isolated from the main component be-
cause they were represented each by a single full-length
clone (Table S2). This raises the possibility that the baits
might not have been ideal for screening and emphasizes
the importanceofusingmultipleoverlappingclonesperpro-
tein to increase the likelihood of generating functional or
properly folded Y2H fusion proteins. Another possible ex-
planation is that thepathogenesis of someof these inherited
ataxiasmay be less directly related to that of other ataxias.
Identification of Literature-Curated and
Evolutionarily Conserved Potential Interactions
In order to expand the interaction dataset, we added rele-
vant direct protein–protein interactions from currently
available human protein–protein interaction networks
(Rual et al., 2005; Stelzl et al., 2005). We also searched
public databases, including BIND (Bader et al., 2003),
DIP (Xenarios et al., 2002), HPRD (Peri et al., 2003), MINT
(Zanzoni et al., 2002), andMIPS (Pagel et al., 2005), to iden-
tify literature-based binary interactions involving the 54
ataxia-associated baits and the 561 interacting prey pro-
teins. We identified 4796 binary protein–protein inter-
actions for our Y2H baits and prey proteins (Table S4)
and incorporated them in the Y2H protein–protein inter-
action map (Figures 4A–4C).
In addition, we searched for potentially conserved inter-
actions, or ‘‘interologs,’’ whose ortholog pairs are known
to interact in other organisms (Walhout et al., 2000). Using
the InParanoid database (http://inparanoid.cgb.ki.se) with
confidence score 1.0, we examined the 615 human pro-
teins (54 baits and 561 preys identified from Y2H screen)
against the yeast, worm, fly, and mouse predicted pro-
teomes. We identified 1527 potential human interologs
from one or more species, and 92/1527 interologs were
known to interact with each other in human (Figures 4A–
4C and Table S4).
Coannotation analysis revealed that 68% and 63%of the
literature-curated and interolog interactions, respectively,are annotated to similar GO compartments (see Supple-
mental Data). This suggests that the literature-curated
and interolog interactions are of a quality similar to interac-
tions identified in our Y2H screens.
In total, we identified 6972 pairs of potential protein–
protein interactions between 3607 proteins, including 18
proteins out of 23 ataxia-causing proteins used for the ini-
tial Y2H screens (Figures 4A–4C). These 6972 interactions
include 119 homodimerization interactions. All protein–
protein interactions are first-, second-, or third-order inter-
actions with ataxia-causing proteins. This ataxia interac-
tion network comprises two integrated components that
we call the ‘‘direct’’ ataxia network and the ‘‘expanded’’
ataxia network. The direct ataxia network contains direct,
first-order protein interactions with ataxia-causing pro-
teins, whereas the expanded network contains additional
second- or third-order interactions.
Properties of the Ataxia-Based Network
We performed a number of analyses to explore the prop-
erties of our ataxia network. The controls for comparison
with our results are networks constructed from a list of
proteins associated with a phenotypically diverse group
of disorders. In addition, we performed a large-scale sim-
ulation study. These control networks, constructed using
an approach similar to the one employed in our study
(see Supplemental Data), determine a space of protein in-
teraction networks that are nucleated around disease pro-
teins but where no bias for a particular disease phenotype
should influence the character of the network. Importantly,
the control networks have similar numbers of proteins, in-
teractors, and connections to the ataxia network. Such
a control permits us to analyze the extent to which the
phenotype-based ataxia network has unusual topological
properties.
To assess our ataxia network against this control, we
calculated the mean shortest-path length between the
ataxia-causing proteins in our network to be 3.11. This
path length is significantly smaller (p < .0004) than the
path length (3.67) between disease proteins in the network
nucleated around 30 disease proteins sampled indepen-
dent of phenotypes. The simulated networks showed the
same property (Figure 4D).
In addition to the mean shortest path length, we
searched for proteins linking pairs of ataxia-causing pro-
teins in relations we call disease triples. Central proteins
in a triple directly interact with two different ataxia-causing
proteins in the pattern: Ataxia protein1-interactor-Ataxia
protein2 (Table S5) as well as quadruples (two interacting
nodes that also bind to two different ataxia-causing pro-
teins: Ataxia protein1-interactor1-interactor2-Ataxia pro-
tein2) (Table S6). Therewere 63 triples and 608 quadruples
in the ataxia network. In contrast, therewere only 42 triples
in the manually constructed, varied phenotype disease
network, and the simulation-based networks had a mean
of 31 triples. Thenumber of triples in the ataxia interactome
was significantly higher (p < .005).Cell 125, 801–814, May 19, 2006 ª2006 Elsevier Inc. 803
Table 1. Inherited Ataxias and Ataxic Mouse Mutants
Symbol
Entrez
Gene ID Proteins
Inherited Ataxias
or Ataxic Mutant Mice
Disease and
Mutational Basis OMIM No.
ATXN1 6310 Ataxin 1 Spinocerebellar ataxia
type 1 (SCA1)
Autosomal dominant
cerebellar ataxia, CAG
repeats/coding
164400
ATXN2 6311 Ataxin 2 Spinocerebellar ataxia
type 2 (SCA2)
Autosomal dominant
cerebellar ataxia, CAG
repeats/coding
183090
ATXN3 4287 Ataxin 3 Spinocerebellar ataxia
type 3 (SCA3) /
Machado-Joseph
disease
Autosomal dominant
cerebellar ataxia, CAG
repeats/coding
109150
CACNA1A 773 Calcium channel,
voltage-dependent,
P/Q type,
alpha 1A subunit
Spinocerebellar ataxia
type 6 (SCA6)
Autosomal dominant
cerebellar ataxia, CAG
repeats/coding
183086
ATXN7 6314 Ataxin 7 Spinocerebellar ataxia
type 7 (SCA7)
Autosomal dominant
cerebellar ataxia, CAG
repeats/coding
164500
TBP 6908 TATA box binding
protein
Spinocerebellar ataxia
type 17 (SCA17)
Autosomal dominant
cerebellar ataxia, CAG
repeats/coding
607136
ATN1 1822 Atrophin 1 Dentatorubropalli-
doluysian atrophy
(DRPLA)
Autosomal dominant
cerebellar ataxia, CAG
repeats/coding
125370
ATXN10 25814 Ataxin 10 Spinocerebellar ataxia
type 10 (SCA10)
Autosomal dominant
cerebellar ataxia,
ATTCT repeats/Intronic
603516
PPP2R2B 5521 Protein phosphatase 2
(formerly 2A), regulatory
subunit B (PR 52), beta
isoform
Spinocerebellar ataxia
type 12 (SCA12)
Autosomal dominant
cerebellar ataxia, CAG
expansion/50-UTR
604326
PRKCG 5582 Protein kinase C,
gamma
Spinocerebellar ataxia
type 14 (SCA14)
Autosomal dominant
cerebellar ataxia,
Missense mutations
605361
FXN 2395 Frataxin Friedreich ataxia
(FRDA)
Ausosomal recessive
ataxia, GAA
expansion/Intronic
229300
ATM 472 Ataxia telangiectasia
mutated
Ataxia telangiectasia
(A-T)
Autosomal recessive
cerebellar ataxia, Point
mutations, deletions
208900
AGTPBP1 23287 ATP/GTP binding
protein 1
Purkinje cell
degeneration
(Nna1 pcd, pcd) mutant
mouse
Autosomal recessive
cerebellar ataxia
606830
APTX 54840 Aprataxin Ataxia with
oculomotor apraxia
(AOA1)
Autosomal recessive
cerebellar ataxia,
Insertion,
deletion, missense
mutations
208920
SACS 26278 Sacsin Spastic ataxia
of Charlevoix-
Saguenay
Autosomal recessive
spastic ataxia, Deletion
270550804 Cell 125, 801–814, May 19, 2006 ª2006 Elsevier Inc.
Table 1. Continued
Symbol
Entrez
Gene ID Proteins
Inherited Ataxias
or Ataxic Mutant Mice
Disease and
Mutational Basis OMIM No.
AIF (PDCD8) 9131 Programmed cell
death 8 (apoptosis-
inducing factor)
Harlequin (Hq) mutant
mouse
X-linked, Progressive
neuronal degeneration
in cerebellum,
Proviral insertion
300169
RORA 6095 RAR-related orphan
receptor A
Staggerer (sg) mouse Autosomal recessive
cerebellar ataxia,
Deletion
600825
PSAP 5660 Prosaposin Purkinje cell
degeneration
Autosomal recessive
Purkinje cell
degeneration
by Saposin D knockout
176801
PRND 23627 Prion protein 2
(dublet)
Purkinje cell
degeneration
Autosomal dominant
Purkinje cell
degeneration
by increased
expression
of Doppel
604263
PRNP 5621 Prion protein
(p27-30)
(Creutzfeld-Jakob
disease, Gerstmann-
Strausler-Scheinker
syndrome, fatal familial
insomnia)
Purkinje cell
degeneration
Autosomal recessive
Purkinje cell
degeneration
176640
AF4 4299 Myeloid/lymphoid or
mixed-lineage
leukemia
(trithorax homolog,
Drosophila);
translocated
to, 2
Robotic mouse Autosomal dominant
cerebellar ataxia,
Missense mutations
159557
ERCC5 2073 Excision repair
cross-complementing
rodent
repair deficiency,
complementation
group 5
(xeroderma
pigmentosum,
complementation
group G [Cockayne
syndrome])
Purkinje cell
degeneration
Autosomal recessive
ataxia
133530
QKI 9444 Quaking homolog, KH
domain RNA binding
(mouse)
Quaking mouse Autosomal recessive
mouse mutation, ataxia
609590To determine whether the properties of the ataxia net-
work are compatible with the known topological charac-
teristics of protein interaction networks (Barabasi and
Oltvai, 2004; Albert, 2005), we investigated the degree dis-
tribution P(k) of the participating proteins and found that
our disease network shows a scale-free degree distribu-
tion similar to that of other interactome studies of modelorganisms. Yet as Figure 4E shows, for the combined
two-hybrid and literature-curated human interactome
(Rual et al., 2005), the value of the degree exponent is
2.7 ± 0.2, considerably higher than the value 2.2 ± 0.1 ob-
tained for the ataxia network. This is somewhat unex-
pected, as a topologically unbiased subset of a scale-
free network should display the same exponent as theCell 125, 801–814, May 19, 2006 ª2006 Elsevier Inc. 805
Figure 1. Generation of a Protein Interac-
tion Network for Inherited Cerebellar
Ataxias
(A) Schematic diagram illustrates two major
steps: (1) identification of Y2H interactions from
three Y2H screens of the hORFeome and the
adult human brain cDNA library; (2) searching
for and adding literature-curated and evolution-
arily conserved interactions, Interologs.
(B) Experimental Y2H interaction data for 54
ataxia-associated proteins.full network. As we show in the Supplementary Data, such
a difference emerges each time the network is con-
structed around a selected set of proteins. Indeed, high-
degree proteins will be overrepresented in the sample,
as the probability that they will interact with the ataxia
proteins is proportional to their degree k. Therefore, the
exponent of the ataxia subnetwork should be one less
than the exponent of the full network. Given, however,
that the protein interaction network has a hierarchical
structure (Yook et al., 2004) and displays degree–degree
correlations (Maslov and Sneppen, 2002), the difference
between the two exponents will be less than one. Based
on these data, we predict that future studies that focus
on the neighborhood of a selected group of proteins will
likely encounter a similar effect, resulting in an exponent
that is smaller than the exponent obtained for the whole
network. From a biological perspective, this means that
in all studies focused on the neighborhood of selected
disease proteins, the hubs will be overrepresented in
comparison to a random sample of a similar number of
proteins.806 Cell 125, 801–814, May 19, 2006 ª2006 Elsevier Inc.Biological Functions of Proteins in the Ataxia
Network
To ascertain which biological functions are associated
with cerebellar ataxias and PC degeneration, we applied
GO term enrichment analysis to the ataxia network (Young
et al., 2005). GO term analysis was applied to the network
as a whole as well as to 44 cohorts. The cohorts were de-
fined as those protein sets that interact directly with each
ataxia-causing protein as well as each collection of first-
and second-order interactors (the union of the proteins
that directly interact with ataxia-causing proteins as well
as their interactors). GO analysis was also applied to the
proteins linking any pair of ataxia-causing proteins through
a ternary or quaternary sequence of interactions. The
full collection of results can be viewed at http://franklin.
imgen.bcm.tmc.edu/ppi/.
Applying themost stringent criteria, we identified 56 GO
biological process categories, 13 GO cellular component
categories, and 13 molecular functions as overrepre-
sented in the ataxia network compared to what would
be expected from a random collection of proteins
Figure 2. Verification of Y2H Interactions by co-AP Assays in Human Cells
Ten representative examples of co-AP assays from Core-1 and Core-2 Y2H datasets are shown. Top panels show expression of Myc-tagged prey
proteins after affinity purification on glutathione-Sepharose 4B bead, demonstrating binding to GST-tagged bait proteins (+) or to GST alone ().
Middle and bottom panels show expression levels of Myc-prey and GST-bait proteins, respectively. Interacting pairs are shown in Table S3 with
the lane number. All figures of co-AP assays have similar configurations unless otherwise indicated.(Figure 5). The biological process GO categories with sig-
nificantly enhanced representation in the expanded ataxia
network include transcriptional regulation, RNA splicing,
ubiquitination, cell cycle, and a few others. The cellular
component categories enriched in the GO term analysis
include the nucleus, proteasome complex, spliceosome
complex, and nuclear membrane. The molecular function
enriched GO categories include transcription factor bind-
ing, transcription cofactor activity, DNA binding, and ki-
nase inhibitor activity. The GO term analysis data are con-
sistent with previous genetic studies illustrating that many
genetic modifiers belong to GO categories such as tran-
scriptional regulation, RNA splicing, and protein degrada-
tion (Fernandez-Funez et al., 2000; Cummings et al., 2001;
Zoghbi and Botas, 2002; Ghosh and Feany, 2004).
Comparing the Inherited Ataxia Network with Human
Diseases in the OMIM Database
To see if any newly identified interacting proteins in the
ataxia network are associated with human diseases, we
searched the OMIM disease database. Interestingly, we
uncovered Purkinje cell atrophy associated protein-1
(Puratrophin-1; also called DKFZP434I216 or PLEKHG4),
a pleckstrin homology domain containing guanine-nucle-
otide exchange factor (GEF) for Rho GTPases, as a Coilin
(COIL)-interacting protein in our Y2H screen (Table S3).
Puratrophin-1 was recently implicated in the etiology of
the 16q22.1-linked autosomal dominant cerebellar ataxia
(OMIM #117210), and the protein was found in aggregates
in PCs (Ishikawa et al., 2005). Interestingly, our data link
Puratrophin-1 to Ataxin-1 (ATXN1), which causes spino-
cerebellar ataxia type 1 (SCA1), through interactions withCOIL (Figure 6A and Table S4). This suggests that SCA1
and the 16q22.1-linked autosomal dominant cerebellar
ataxia might share certain disease processes. This finding
also suggests that our network could contain candidate
genes for ataxias whose genes have not yet been identi-
fied. Amongst theprimary interactors of the ataxia-causing
proteins, 57 proteins are associated with human diseases
listed in OMIM. The expanded network, which includes
secondary interactions and beyond, contains 496 of the
disease proteins listed in OMIM (Table S4). Thus, the net-
work should be valuable for investigators studying these
diseases.
Linking Genetic Modifiers with Protein–Protein
Interaction Networks
To verify the in vivo relevance of the ataxia network, we
turned our attention to animal models of inherited ataxias
to see if any of the identified interacting proteins affect the
neurodegenerative phenotypes. Genetic modifier screens
using Drosophila and mouse disease models have identi-
fied factors that modulate the toxicity of disease-causing
proteins, although their biochemical and molecular rela-
tionship to the disease proteins is not known even in the
model organisms (Fernandez-Funez et al., 2000; Kazemi-
Esfarjani and Benzer, 2000; Zoghbi and Botas, 2002;
Ghosh and Feany, 2004). These modifiers belong to sev-
eral different classes that include protein folding and deg-
radation pathways, RNA metabolism, and transcription.
Many human orthologs of the genetic modifiers previously
described in Drosophila and mouse SCA1 and SCA3
models (Fernandez-Funez et al., 2000; Ghosh and Feany,
2004) were identified in our Y2Hscreen aspotential proteinCell 125, 801–814, May 19, 2006 ª2006 Elsevier Inc. 807
Figure 3. Network Graph of the Y2H Interactions
Blue nodes depict proteins corresponding to genes mutated in ataxias; red nodes depict proteins that are paralogs or interact with ataxia-causing
proteins; and yellow nodes depict Y2H interactors from this screen. Purple and green edges show protein interactions from the hORFeome and brain
cDNA library screens, respectively. All edges are either first- or second-order interactions to ataxia-causing proteins.interactors of the disease-causing proteins (Figure 6A).We
verified some of the new Y2H interactions for one disease-
causing protein, ATXN1, to further support the finding that
the genetic interaction is due to direct physical interac-
tions. Two SCA1 genetic modifiers, Ataxin-2 (ATXN2) and
RBPMS (ortholog of Drosophila ‘‘Couch potato’’), showed
a strong physical interaction with ATXN1 by co-AP assays
(Figure 6B). We further determined the domains of ATXN1
required for the interactionwithRBPMSusing theY2Hsys-
tem (Figure 6C) and co-AP assays (Figure 6D). Our results
suggest that the N-terminal portion of ATXN1 is required
for the interaction with RBPMS. The finding that a subset
of the interacting proteins are established genetic modi-
fiers of disease-related phenotypes suggests that the
ataxia network will most likely reveal novel genetic modi-
fiers for the ataxias.
Interestingly, we found that some of the ATXN1 genetic
modifiers also physically interactwith other ataxia-causing
proteins. For example, RBPMS is one of the main hubs in
the network interactingwithmany other proteins, including
two other cerebellar ataxia-causing proteins, Atrophin-1
(ATN1) and Quaking (QKI) (Figure 6A). This suggests that
some genetic modifiers for a specific disease could also
modify other diseases of the same class and might play
a key role in a common molecular pathway. Taken to-
gether, data from the protein interaction network can be
combined with data from the genetic modifier network to808 Cell 125, 801–814, May 19, 2006 ª2006 Elsevier Inc.study biological functions and pathogenic mechanisms
of disease-causing proteins.
DISCUSSION
Several human inherited cerebellar ataxias and many
ataxic mouse mutants share clinical and pathological fea-
tures such as loss of balance and coordination due to Pur-
kinje cell degeneration. To determine whether shared mo-
lecular pathways can explain the phenotypic similarities,
we developed an interaction network for proteins involved
in inherited cerebellar ataxias. The ataxia network was
built first using Y2H screens and then expanded by incor-
porating literature-curated and evolutionarily conserved
interactions. This network revealed that several ataxia
proteins interact and that indeed there are common pro-
cesses and pathways involved in this class of neurode-
generative diseases. Furthermore, the network should
provide insight into the normal functions of each individual
ataxia protein and reveal novel candidate genes for dis-
eases with overlapping phenotypes.
Generation and Characterization of the Ataxia
Protein Network
Y2H screens provide an efficient way to develop protein–
protein interaction networks. The limitations of Y2H-
based assays, however, include high false-positive and
Figure 4. Generation and Analysis of the Ataxia Network
(A and B) Literature-curated interactions (LCIs) and Interologs are searched (A) for only 23 ataxia-causing proteins or (B) for all 54 ataxia-associated
proteins and 561 Y2H-interacting proteins.
(C) Expanded ataxia network graph. Proteins are shown as yellow nodes. Interactions are shown as three different edge colors: green (Y2H interac-
tions in this study), blue (LCI), and red (Interolog). All edges are first-, second-, or third-order interactions with ataxia-causing proteins.
(D) Mean path length. Any two ataxia-causing proteins in our network are connected via 3.11 links on average (red line), which is significantly (p <
.0004) shorter than amean path length between two proteins in a network based on phenotypically unrelateddiseases (3.67, blue line) or in a simulated
network of unrelated random diseases (3.65, black line).
(E) The degree distribution (normalized histogram) of the ataxia network in the left panel. Unfilled circles denote the probability that a protein will have
exactly k links, and filled symbols correspond to the logarithmically binned version of the degree distribution, providing similar statistical weights in
each bin. Both representations follow power laws P(k) (k + k0)-g, where the exponent is g = 2.2 ± 0.1 (the black line indicates the fit). The right panel
shows with diamonds the degree distribution of the human interactome network expanded with literature-curated data, and the fit to the logarithmi-
cally binned points is P(k)  (k + 2.3)-2.7 ± 0.2. In contrast, for the subnetwork generated by taking interactions of at most third order with the ataxia-
causing proteins (triangles), the best fit to the degree distribution changes to P(k)  k-2.0 ± 0.1.Cell 125, 801–814, May 19, 2006 ª2006 Elsevier Inc. 809
Figure 5. The Enriched GO Categories of the Ataxia Network
The pie charts depict the relative number of GO terms enriched in each of the three branches of theGO structurewhen using thewhole genome and/or
the hORFeome as reference distributions. Enriched categories are identified as those significant (p < 0.05) after adjusting for multiple testing. The bar
charts depict the enrichedGO terms from the common set (whole genome and hORFeome). The number of bars shown is less than the total number of
common enriched categories because bars represent only the terminal GO terms. The length of the bar is the standardized enrichment score.false-negative discovery rates. Therefore, whenwe set out
to develop the ataxia-based network, we implemented
several strategies to reduce these limitations. We used
a stringent version of the Y2H system designed to express
fusion proteins at low levels, permitting the identification
of protein–protein interactions at physiological concentra-
tions and minimizing the likelihood of false-positive inter-
actions (Vidalain et al., 2004; Rual et al., 2005). The high
validation rate of our Y2H interaction datasets by indepen-
dent co-AP assays in mammalian cells (83%) as well as
the biological information gathered from informatic-based
analyses support the notion that our network has a low
rate of false-positives and is of high quality.
To decrease the false-negative discovery rate, we
screened hORFeome and adult human brain cDNA librar-
ies. The hORFeome has the advantage of being nearly810 Cell 125, 801–814, May 19, 2006 ª2006 Elsevier Inc.90% normalized (i.e., >88% of the clones are equally rep-
resented in the library). In addition, the hORFeome allowed
us to screen both AD- andDB-hORFeome reciprocally us-
ing both DB- and AD-ataxia fusion proteins, respectively.
This approach alsomade it possible to screen some ataxia
baits thatwere autoactivating at theDBposition by placing
them in the AD-position (Du et al., 1996). Using an adult
brain cDNA library, we had the added advantage that mul-
tiple AD-cDNAs in that library encode fragments with dif-
ferent AD-fusion junctions representing each protein and
its isoforms. Our results show that screening both libraries
was indeed a worthwhile effort, given that only 29 out of
770 interaction pairs were identified as common.
There are several possible reasons that these two Y2H
screens yielded largely different subsets of interacting
proteins. The most prominent contributing factor is the
Figure 6. Genetic and Protein Interaction Data Reveal Functional Relevance of the Ataxia Network
(A) Graphic representation of an ATXN1 subnetwork; several interactors of ATXN1 proved to be genetic modifiers as well. Nodes depict interacting
proteins in yellow, ataxia-causing proteins in blue, and genetic modifiers of SCA1 pathology in orange. Squares and circles indicate Y2H baits or
preys, respectively. Edge colors define interactions: green (this study) and blue (LCI).
(B) Co-AP validation of interactions. GST-tagged proteins are GST alone (), GST-ATXN1 [30Q] (W), and GST-ATXN1 [84Q] (M).
(C and D) Mapping of ATXN1’s domain that binds RBPMS. Deletion constructs of ATXN1 were tested for binding to RBPMS by Y2H assays (C) and by
co-AP assays in HEK293T cells (D).difference between the libraries themselves: The hOR-
Feome has about 8000 clones, whereas the brain cDNA li-
brary has at least two to three times that representation of
clones. The representation of specific proteins in each
library is also vastly different (full-length clone versus
full-length and fragments for hORFeome and brain cDNA
libraries, respectively). Previous work has shown that
many biologically relevant protein–protein interactions
cannot be detected in the Y2H assay when using full-
length proteins (Flajolet et al., 2000; Legrain and Selig,
2000). In fact, our own data show that baits containing
full-length aswell as portions of the coding region of a spe-
cific gene are more successful at identifying protein part-
ners than the full-length bait by itself. For example, the
hORFeome screen yielded on average 8.34 interactions
per gene for baits represented by both full-length and frag-
ment clones in contrast with 1.19 interactions per gene
represented only by full-length bait. In addition, full-length
baits may fail to identify interacting proteins because they
do not generate properly folded Y2H fusion proteins. The
use of multiple overlapping protein fragments may in-
crease the likelihood of exposing protein interfaces re-
quired for successful interactions in Y2H screening. An-
other factor contributing to discordances between the
two Y2H screens is that each screen is done using totallydifferent methodology (mating versus cotransformation
screen). Thus, it is not surprising that their sensitivity might
differ. Lastly, it is possible that one method might yield
a higher false-positive rate than the other. Our data, how-
ever, exclude this as a major factor, given the similar val-
idation rate for hORFeome and cDNA library based inter-
actions. In summary, the findings of this study suggest
that screening both libraries increases the chances of
identifying interacting proteins.
Combining a stringent Y2H screen with literature-
curated and evolutionarily conserved interaction data,
we generated a large protein–protein interaction network
focused on approximately 20 proteins associated with in-
herited ataxias. After developing the ataxia network, we
sought to determine whether the ataxia-causing proteins
were more directly or indirectly connected to each other
than would be expected in a similar network developed
around proteins involved in diseases with unrelated phe-
notypes. The data clearly show that the ataxia network
is significantly different from a disease network based on
a similar number of proteins with nonoverlapping disease
phenotypes. These differences were apparent in both the
path length between disease-causing proteins (shorter in
the ataxia network) and the number of triples connecting
two disease proteins (higher in the ataxia network).Cell 125, 801–814, May 19, 2006 ª2006 Elsevier Inc. 811
To determine whether the protein–protein interactions
in our network are biologically relevant (Jansen et al.,
2003; Jansen and Gerstein, 2004; Rual et al., 2005), we
used informatic approaches. GeneOntology (GO) analysis
revealed that interacting proteins colocalize in subcellular
compartments and are similarly annotated. Overall, the
nucleus and nuclear subdomains are the dominant sub-
cellular compartments implicated in the ataxia network.
GO term analysis of the network revealed enrichment for
specific biological functions.
Biological Implications of the Ataxia Network
A surprising and interesting outcome of this study is that
the majority (18/23) of the ataxia-causing proteins inter-
act either directly or indirectly. This was certainly not ex-
pected for such a large proportion of proteins; indeed,
none of the 23 ataxia-causing proteins were known to in-
teract with each other. Given the interconnectivity and
short path length between the ataxia gene products, this
network is likely to contain candidate genes for the 20 or
more inherited ataxias whose causative genes have not
yet been identified (Table S7). A case in point is the exam-
ple of Puratrophin-1. When we started this study, we did
not know that Puratrophin-1 is associated with an in-
herited ataxia, so it was not included among the baits.
After completing the Y2H screen, Puratrophin-1 was iden-
tified as an interactor of COIL (an interactor of ATXN1). In
themeantime, Ishikawa et al. (2005) reported that Puratro-
phin-1 is implicated in 16q22.1-linked cerebellar ataxia.
We demonstrated that many human orthologs of ge-
netic modifiers identified inDrosophila andmurine disease
models interact directly with the ataxia-causing proteins.
This is also quite interesting given that the majority of
such modifiers were not known to be physical interactors
and were not selected as baits in our study. Having shown
that several genetic modifiers are physical interactors of
ataxia-causing proteins, we would predict that some of
the physical interactors are modifiers of ataxia pheno-
types. Identifying such modifiers might expand the list of
potential targets for therapeutic interventions. The finding
that many protein interactions involve orthologous modi-
fiers studied in model organisms supports the fact that
many biologically relevant protein–protein interactions are
conserved throughout evolution. Therefore, searching for
evolutionarily conserved interactions in other organisms
as we did in this study should provide insight into the func-
tions of a protein and its role in pathogenesis. Protein–pro-
tein interaction networks generated in model organisms
such as yeast (Uetz et al., 2000; Ito et al., 2001), worm
(Walhout et al., 2000; Li et al., 2004), and fruit fly (Giot
et al., 2003) will be a valuable resource for identifying func-
tionally conserved interactions in the human and their rel-
evance to different diseases or biological processes.
Human protein–protein interaction maps have been
generated (Rual et al., 2005; Stelzl et al., 2005). Although
such maps are still far from being complete, they will def-
initely provide a framework upon which to expand and
deepen the network for many biological studies. In this812 Cell 125, 801–814, May 19, 2006 ª2006 Elsevier Inc.study we constructed an expanded network around the
ataxias to deepen the network around specific disease
processes and to provide a rich source of proteins that
will permit in-depth functional studies of each specific
ataxia protein.
Interestingly, some components in the network interact
with only a single ataxia-causing protein, but others called
‘‘hubs’’ interconnect many (Barabasi and Albert, 1999).
For example, three proteins (RBM9, A2BP1, and RBPMS)
represent one of the main hubs in the ataxia network and
interact with several different ataxia-causing proteins
(Figure 6A). These proteins are involved in RNA binding
or splicing (Jin et al., 2003; Nakahata and Kawamoto,
2005; Underwood et al., 2005) and genetically modify neu-
rodegeneration in animal models (Fernandez-Funez et al.,
2000). These data reveal one potential common mecha-
nism of pathogenecity in this class of diseases and sug-
gest that a subset of inherited ataxias might represent dis-
orders of RNA splicing. This result is interesting in light of
the discovery that alternative splicing defects are at the
root of pathogenesis of mice lacking the protein NOVA,
which is implicated in paraneoplastic opsoclonus myoclo-
nus ataxia (POMA) syndrome (Ule et al., 2003; Ule et al.,
2005). Identifying such hubs and modifiers might focus
pathogenesis research efforts on key proteins and inter-
actors relevant to the broader class of ataxias rather
than a single disorder.
In summary, the data in this study show that a protein–
protein interaction network for seemingly unrelated gene
products involved in a group of different diseases that
share clinical and pathological phenotypes (inherited cer-
ebellar ataxias) has a high rate of verifiable interactions, is
highly connected, and has the potential to reveal key me-
diators of pathogenesis. The finding that many genetic
modifier proteins show direct physical interactions with
the corresponding disease protein validates and under-
scores the power of both approaches. Lastly, we propose
that phenotype-based protein–protein interaction studies
can be applied tomany human diseases, particularly com-
mon disorders that are sporadic in the majority of cases
but do result from single gene defects in a small subset
of patients. Included among these are Parkinson disease,
diabetes, and hypertension. Such phenotype or disease-
based interaction networks might reveal candidate dis-
ease genes, novel modifiers, and key pathogenic mecha-
nisms that could be targeted therapeutically.
EXPERIMENTAL PROCEDURES
Yeast Two-Hybrid Screens
Starting from cDNAs of genes mutated in inherited ataxias, full-length
ORFs or various fragments thereof were amplified by PCR and cloned
into the pDONR223 ‘‘Donor’’ vector using the Gateway system as de-
scribed (Rual et al., 2004). From the resulting ‘‘Entry’’ clones, ORFs or
fragments were transferred individually into pDB-dest and pAD-dest-
CYH Gateway-compatible ‘‘Destination’’ vectors to generate DB-
ataxia and AD-ataxia fusion constructs, respectively.
To screen the hORFeome, we performed two independent mating
Y2H screens in a 96-well format as described (Rual et al., 2005). The
DB-ataxia baits were used against the AD-hORFeome library in the
first screen, whereas the AD-ataxia constructs were used in the sec-
ond screen. DB-ataxia baits that did not show autoactivation (Table
S2) were used to screen an adult human brain cDNA library (ProQuest,
Invitrogen). See Supplemental Data for details about vectors and
screens.
Coaffinity Purification Experiments
The co-AP experiments were performed in human HEK293T cells as
described (Rual et al., 2005). See Supplemental Data for details.
Bioinformatics Analyses
Three types of analyses were performed on the network: validation of
the protein interactions based on GO annotation data, analysis of the
network topology, and GO content analysis. The calculations on the
network were largely conducted in the R statistical programming envi-
ronment (Gentleman and Ihaka, 1996) using the RBGL and graph
package extensions. See Supplemental Data for more details.
Supplemental Data
Supplemental Data include one figure, seven tables, Experimental Pro-
cedures, and References and can be found with this article online at
http://www.cell.com/cgi/content/full/125/4/801/DC1/.
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